Workflow
YILING PHARMACEUTICAL(002603)
icon
Search documents
以岭药业(002603) - 2024 Q2 - 季度财报
2024-08-27 11:34
Financial Performance - The company's operating revenue for the first half of 2024 was CNY 4,604,485,816.89, a decrease of 32.19% compared to CNY 6,790,561,553.22 in the same period last year[10]. - The net profit attributable to shareholders for the first half of 2024 was CNY 530,457,109.15, down 66.97% from CNY 1,606,021,016.98 in the previous year[10]. - The net profit after deducting non-recurring gains and losses was CNY 504,681,264.63, reflecting a decline of 67.24% compared to CNY 1,540,608,040.88 in the same period last year[10]. - The net cash flow from operating activities was CNY 264,166,879.91, a decrease of 61.18% from CNY 680,537,848.22 in the previous year[10]. - The basic earnings per share for the first half of 2024 was CNY 0.3175, down 66.97% from CNY 0.9613 in the same period last year[10]. - The total assets at the end of the reporting period were CNY 16,951,526,200.11, a slight decrease of 0.16% from CNY 16,979,326,536.89 at the end of the previous year[10]. - The net assets attributable to shareholders at the end of the reporting period were CNY 11,478,988,389.47, an increase of 0.26% from CNY 11,449,722,316.51 at the end of the previous year[10]. - The weighted average return on equity for the first half of 2024 was 4.53%, down 9.32% from 13.85% in the same period last year[10]. - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[1]. Research and Development - The company has developed 14 patented new drugs, with a strong focus on cardiovascular and respiratory diseases, establishing a leading position in the industry[16]. - The company has a robust research and development platform for innovative traditional Chinese medicine, guided by the theory of collateral diseases[16]. - The company is focusing on R&D in key disease areas such as cardiovascular, respiratory, and endocrine systems, with ongoing projects at various stages of clinical trials[100]. - The company has received clinical approval for products targeting diseases in rheumatology, digestive, ENT, and pediatrics, with ongoing research in cardiovascular and respiratory systems[100]. - The company continues to invest in research and development, with a focus on innovative therapies and expanding its market reach[46]. - The company has established a high-quality research and management team, including academicians and returning overseas experts, to strengthen its innovative drug development capabilities[95]. - The company has implemented a brand marketing strategy, transforming from product management to brand management, significantly enhancing its reputation as a technology innovation enterprise in the pharmaceutical industry[96]. - The company has completed several clinical studies for its products, establishing a strong evidence base for clinical promotion[86]. - The company is actively engaged in ongoing evidence-based medical research for multiple marketed products[86]. Product Development and Market Expansion - The company has submitted registration applications in over 50 countries for its products, with 7 registrations approved in Guatemala, Chile, and the UAE[18]. - The company is actively expanding its international market presence, with a dual registration strategy for generic drugs in both domestic and international markets[17]. - The company has launched a unique formula health food product in the first half of 2024, emphasizing the integration of traditional Chinese medicine and modern technology[124]. - The company is expanding its market presence, targeting an increase in distribution channels by 30% in the next year[82]. - The company plans to implement a new marketing strategy focusing on digital platforms, which is projected to increase customer engagement by 40%[82]. - The company has established a comprehensive sales network covering online and offline channels, with a focus on e-commerce as a core business, including partnerships with JD Health and Alibaba Health[125]. - The company has integrated its business model to combine online and offline sales, domestic and international markets, and pharmaceutical sales with the health industry, creating a core competitive advantage[94]. Clinical Efficacy and Guidelines - Tongxinluo capsules demonstrated a 36% reduction in major adverse cardiovascular events within 30 days for STEMI patients, and a 30% reduction in cardiovascular death risk[22]. - The clinical study published in JAMA included 3,797 STEMI patients from 124 hospitals, confirming the efficacy of Tongxinluo in improving myocardial blood flow and heart function[22]. - Tongxinluo capsules received 8 Class I recommendations and 9 Class A recommendations for various coronary heart disease treatments in the recently published expert consensus[24]. - Shijiazhuang Yiling Pharmaceutical's Sansongyangxin capsules showed a 40% reduction in recurrence risk for persistent atrial fibrillation patients post-radiofrequency ablation[26]. - Both Tongxinluo and Sansongyangxin capsules are included in the "Guidelines for Rational Drug Use in Coronary Heart Disease" to promote correct and standardized medication practices[27]. - The clinical research on Tongxinluo has been published in top-tier medical journals, enhancing its credibility and acceptance in the medical community[22]. - The company’s products have been recognized for their clinical value through evidence-based medicine research, enhancing their trust among healthcare professionals and patients[86]. Financial Management and Investments - The company has invested 150 million CNY in new technology for product development, aiming to improve efficiency and reduce costs by 25%[82]. - The company has committed to using the raised funds primarily for working capital and specific projects, with no changes in the intended use reported[146]. - The company has not engaged in any major related party transactions or non-operating fund occupation during the reporting period, ensuring financial integrity[185][186]. - The company has not reported any overdue or unrecovered amounts from its wealth management investments, indicating sound financial management[192]. Environmental and Social Responsibility - The company is committed to sustainability initiatives, aiming to reduce carbon emissions by 30% over the next five years[82]. - The company has established an environmental control platform to enhance the efficiency of wastewater treatment systems, reducing labor load while ensuring stable operations[180]. - The company has built over 50 traditional Chinese medicine cultivation bases across the country, promoting rural revitalization through a "company + base + farmer" model[182]. - The company donated over hundreds of millions of yuan to various charitable activities, including the "Health Village China Tour" project, enhancing grassroots medical service levels[182]. - The company is committed to social responsibility, focusing on employee development, environmental protection, and community contributions[181]. Market Trends and Challenges - The retail end of the cold medication market saw a decline of 12.42% in the first half of 2024, indicating a challenging market environment[69]. - The company faces risks related to the dilution of return on net assets due to the time required for the internationalization of chemical preparations and modern traditional Chinese medicine projects to achieve expected returns[161]. - The company is monitoring the prices of key raw materials, which are subject to fluctuations due to natural growth and seasonal harvesting, and is implementing strategies to mitigate these risks[158]. - The company is facing management risks due to the complexity of its organizational structure and the need for improved management capabilities as it expands[159].
以岭药业:半年度非经营性资金占用及其他关联资金往来情况汇总表
2024-08-27 11:32
石家庄以岭药业股份有限公司 2024 年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位:万元 非经营性资金 占用 资金占用方名称 占用方与上市 公司的关联关 系 上市公司核 算的会计科 目 2024 年期初 占用资金余 额 2024 年半年度 占用累计发生 金额(不含利 息) 2024 年半年 度占用资金的 利息(如有) 2024 年半年 度偿还累计 发生金额 2024 年半年 度期末占用 资金余额 占用形成原 因 占用性质 控股股东、实 际控制人及其 附属企业 非经营性占用 小计 - - - - 前控股股东、 实际控制人及 其附属企业 非经营性占用 小计 - - - - 其他关联方及 其附属企业 非经营性占用 小计 - - - - 总计 - - - - | 其他关联资金 | | 往来方与上市 | 上市公司核 | 年半年 2024 | 2024 年半年度 | 年半年 2024 | 年半年 2024 | 年半年 2024 | 往来形成原 | 往来性质 (经营性往 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ...
以岭药业:半年报监事会决议公告
2024-08-27 11:32
证券代码:002603 证券简称:以岭药业 公告编号:2024-029 石家庄以岭药业股份有限公司 第八届监事会第八次会议决议公告 特此公告。 石家庄以岭药业股份有限公司 石家庄以岭药业股份有限公司第八届监事会第八次会议于 2024 年 8 月 27 日在公司会议室以现场方式召开。本次会议通知和文件于 2024 年 8 月 16 日以电 话通知并电子邮件方式发出。会议应参加表决监事 3 人,实际参加表决监事 3 人。会议由公司监事会主席高学东主持。本次会议的召集程序、审议程序和表决 方式均符合《公司法》、相关法律法规及本公司章程的规定。 会议以记名投票表决方式审议通过了以下议案并形成决议如下: 一、审议通过了《2024 年半年度报告》及摘要。 监事会认为:董事会编制和审核公司 2024 年半年度报告的程序符合法律、 行政法规和中国证监会的规定,报告内容真实、准确、完整地反映了上市公司的 实际情况,不存在任何虚假记载、误导性陈述或者重大遗漏。 表决情况:同意 3 票,反对 0 票,弃权 0 票。 二、审议通过了《关于 2024 年半年度募集资金存放与使用情况的专项报告》。 监事会认为:公司募集资金的管理、使用及 ...
以岭药业:半年报董事会决议公告
2024-08-27 11:32
证券代码:002603 证券简称:以岭药业 公告编号:2024-028 石家庄以岭药业股份有限公司 《2024 年半年度报告》详见同日巨潮资讯网(www.cninfo.com.cn),《2024 年半年度报告》摘要同日刊登于《中国证券报》《上海证券报》《证券时报》《证 券日报》和巨潮资讯网(www.cninfo.com.cn)。 第八届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚假 记载、误导性陈述或重大遗漏。 石家庄以岭药业股份有限公司第八届董事会第十三次会议于 2024 年 8 月 27 日在公司会议室以现场方式召开。本次会议通知和文件于 2024 年 8 月 16 日以电 话通知并电子邮件方式发出。会议应参加表决董事9人,实际参加表决董事9人。 会议由公司董事长吴相君主持,监事会成员、公司高级管理人员列席了会议。本 次会议的召集程序、审议程序和表决方式均符合《公司法》、相关法律法规及本 公司章程的规定。 会议以记名投票表决方式审议通过了以下议案: 一、审议通过了《2024 年半年度报告》及摘要。 表决情况:同意 9 票,反对 0 票,弃权 0 票。 202 ...
以岭药业:以岭药业董事会关于2024年半年度募集资金存放与使用情况的专项报告
2024-08-27 11:32
石家庄以岭药业股份有限公司董事会 关于 2024 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚假记载、误导性陈 述或重大遗漏。 根据深圳证券交易所印发的《深圳证券交易所上市公司自律监管指引第 1 号—— 主板上市公司规范运作》《深圳证券交易所上市公司信息披露公告格式第 21 号—上 市公司募集资金年度存放与使用情况的专项报告格式》的有关规定及相关格式指引的 规定,将石家庄以岭药业股份有限公司(以下简称"公司"或"本公司")2024 年半年度 募集资金存放与使用情况专项说明如下: 一、募集资金基本情况 (一)实际募集资金金额、资金到位情况 本公司经中国证券监督管理委员会《关于核准石家庄以岭药业股份有限公司非公 开发行股票的批复》(证监许可[2017] 81号)核准,公司采用向特定投资者非公开发 行的方式发行每股面值为人民币1.00元的普通股股票74,720,183.00股,发行价格为每 股人民币17.48元,募集资金总额为人民币1,306,108,798.84元,扣除承销费、保荐费等 发行费用人民币17,300,000.00元,募集资金净额为人民币1 ...
以岭药业:络病理论指导新药研发,中药创新药龙头企业
Xiangcai Securities· 2024-07-23 04:01
证券研究报告 2024 年 07 月 21 日 湘财证券研究所 公司研究 以岭药业(002603.SZ) 络病理论指导新药研发,中药创新药龙头企业 核心要点: 公司评级:增持(首次覆盖) 近十二个月公司表现 -50% -40% -30% -20% -10% 0% 10% 以岭药业 沪深300 | --- | --- | --- | --- | |----------|--------|--------|----------| | % | 1 个月 | 3 个月 | 12 个月 | | 相对收益 | -2 | -17 | -27 | | 绝对收益 | -1 | -17 | -34 | | | | | 300 相比 | 分析师:许雯 证书编号:S0500517110001 Tel:(8621) 50293534 Email:xw3315@xcsc.com 地址:上海市浦东新区银城路88号 中国人寿金融中心10楼 公司以中药产业为核心,化生药与大健康产业协同发展 公司主要从事专利创新中药的研发、生产和销售。在开展创新中药研发的 同时,积极布局化生药和健康产业,构建了专利中药、化生药、健康产业 协同发展、相互促进的医 ...
以岭药业:2023年年度权益分派实施公告
2024-07-11 10:41
证券代码:002603 证券简称:以岭药业 公告编号:2024-027 石家庄以岭药业股份有限公司 2023 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 一、股东大会审议通过权益分派方案等情况 1、石家庄以岭药业股份有限公司(以下简称"公司")2023 年年度权益分 派方案已获 2024 年 5 月 22 日召开的 2023 年年度股东大会审议通过,具体方案 为:以 2023 年 12 月 31 日总股本 1,670,705,376 股为基数,向全体股东每 10 股 派发现金红利 3.00 元(含税),送红股 0 股(含税),不以公积金转增股本。 本次权益分派按分配比例固定原则分配。 2、自分配方案披露至实施期间公司股本总额未发生变化。 3、本次实施的分配方案与股东大会审议通过的分配方案一致。 4、本次实施分配方案距离股东大会审议通过的时间未超过两个月。 二、权益分派方案 本公司 2023 年年度权益分派方案为:以公司现有总股本 1,670,705,376 股为 基数,向全体股东每 10 股派 3.000000 元人民币现金(含税; ...
以岭药业(002603) - 2024 Q2 - 季度业绩预告
2024-07-10 11:41
Financial Performance Expectations - The company expects a net profit of between 433.63 million yuan and 642.41 million yuan for the first half of 2024[3] - Net profit attributable to shareholders is projected to decline by 60% to 73% compared to the same period last year, which reported a profit of 1,606.02 million yuan[3] - The net profit after deducting non-recurring gains and losses is estimated to be between 415.96 million yuan and 616.24 million yuan, also reflecting a decline of 60% to 73% year-on-year[3] - Basic earnings per share are expected to be between 0.26 yuan and 0.38 yuan, down from 0.96 yuan per share in the same period last year[3] Reasons for Performance Decline - The decline in performance is primarily attributed to decreased market demand for respiratory products due to high inventory levels and last year's high base effect[4] Financial Data and Auditing - The earnings forecast has not been audited by the accounting firm, but preliminary discussions indicate no discrepancies[4] - The financial data provided is based on preliminary calculations by the company's finance department and will be finalized in the 2024 semi-annual report[5] Investment Advisory - Investors are advised to make cautious decisions and be aware of investment risks[6]
以岭药业:关于收到药品注册申请受理通知书的公告
2024-07-10 11:41
证券代码:002603 证券简称:以岭药业 公告编号:2024-026 石家庄以岭药业股份有限公司 关于收到药品注册申请受理通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没 有虚假记载、误导性陈述或重大遗漏。 近日,石家庄以岭药业股份有限公司(以下简称"公司")收到国家药品监 督管理局下发的《受理通知书》,由公司提交的"苯胺洛芬注射液"新药注册申 请已获正式受理。现就相关事项公告如下: 一、受理通知书基本内容 申 请 人:石家庄以岭药业股份有限公司 申请事项:境内生产药品注册 产品名称:苯胺洛芬注射液 石家庄以岭药业股份有限公司 董事会 主要结论:根据《中华人民共和国行政许可法》第三十二条的规定,经审查, 决定予以受理。 二、药品的基本情况 苯胺洛芬注射液是公司自主研制的化学药新药。苯胺洛芬注射液从化学结构 上属于芳基烷酸类镇痛抗炎药,可以抑制前列腺素合成,通过阻断炎症介质发挥 镇痛抗炎作用。其临床拟用适应症:用于成人手术后轻至中度疼痛,与阿片类镇 痛药联合用于治疗术后中至重度疼痛。 三、对公司的影响及主要风险提示 根据国家药品注册相关的法律法规要求,上述药品在获国家药品监督管理局 ...
以岭药业:关于使用部分闲置非公开发行募集资金暂时补充流动资金的公告
2024-07-08 10:21
证券代码:002603 证券简称:以岭药业 公告编号:2024-024 一、公司 2017 年非公开发行募集资金基本情况 本公司经中国证券监督管理委员会《关于核准石家庄以岭药业股份有限公司 非公开发行股票的批复》(证监许可[2017] 81 号)核准,公司采用向特定投资者非 公开发行的方式发行每股面值为人民币 1.00 元的普通股股票 74,720,183 股,发 行价格为每股人民币 17.48 元,募集资金总额为人民币 1,306,108,798.84 元,扣 除承销费、保荐费等发行费用人民币 17,300,000.00 元,募集资金净额为人民币 1,288,808,798.84 元。本次发行的保荐人中国国际金融股份有限公司(以下简称 "中金公司")已于 2017 年 2 月 22 日将募集资金净额人民币 1,288,808,798.84 元 汇入公司募集资金专用账户进行专户存储。专户存储情况如下: 单位:人民币元 的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚假 记载、误导性陈述或重大遗漏。 石家庄以岭药业股份有限公司(以下简称"公司""本公司")于2024年7 月8日召开第八届 ...